AstraZeneca is a company that makes bio-carrier solution for humanized antibody that has been used in the drug delivery process in human physiological system. The manager is considering adding a nonmetal-based nanoparticle (Type C or Si) to its solution to increase the product performance at medium temperatures. The costs associated with each type are estimated. If the company's MARR is 15% per year, then: Type C -150,000 -92,000 30,000 Type Si -280,000 -74,000 70,000 Initial cost, $ Annual cost, $/yr Salvage value of process units, $ Estimated market value of the process unit at the end of year 7 Life, years 25,000 45,000 3 a) What is the LCM b) Draw cash flow diagram for cost estimates for Type C and Type Si based on the LCM c) Using LCM, Study Period of 6 and Analysis Period of 7 years determine the present worth of the two types (C & Si), d) Which nanoparticle type should the company select for each method (LCM, Study Period and Analysis Period)? Give reasons for your choice